A Phase 3 interventional study of Adalimumab in Rheumatoid Arthritis, sponsored by Abbott. Completed at 16 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2011-06-21.
Sponsored by Abbott · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 56th largest by enrollment, is one of 5 that started in 2006, is one of 36 in phase 3, and was the 21st registered.
3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Ages 18+
Qilu Hospital of Shandong University · Sites in China
Ages 18–80
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 39 · Phase 4 33
First in 2000; this study’s year is marked. 5 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 88 is close to the median of 96 across 2,223 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 160 across the 87 interventional studies. Of the 73 that completed or were terminated, 43 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 87 have an industry lead sponsor. The 10 most frequent:
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
33 studies in Arthritis, Rheumatoid by Abbott: none open now, none under way, none of them phase 3. Of 30 finished, 19 (63%) have results posted.
Among the 33 studies in Arthritis, Rheumatoid by Abbott, this one is the 19th largest by enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2006, is one of 14 in phase 3, and was the 16th registered.
Abbott’s Arthritis, Rheumatoid studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Abbott’s 33 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the long-term safety of subcutaneous (SC) self-injections (by the subject or subject's family member) of adalimumab in adult Japanese subjects with Rheumatoid Arthritis in an open-label study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adalimumab 40 mg or 80 mg (same dose subject was receiving in preceding Study M03-651 \[NCT 00235872\]) subcutaneously (sc) administered every other week (eow) until approval of adalimumab in Japan
Biological: Adalimumab
40 mg or 80 mg every other week (eow), subcutaneous (sc), self-injection
Also known as: Humira, ABT-D2E7
Number of Subjects With American College of Rheumatology (ACR) Criteria Improvement of at Least 20%, 50%, and 70% (ACR20/50/70 Responders, Respectively)
Number of responders with ACR criteria improvement consisting of 20%, 50%, and 70% (ACR20, ACR50, and ACR70, respectively) reduction in tender or swollen joint counts (TJC or SJC, respectively) and 20%, 50%, and 70% improvement, respectively, in 3 of the following 5 criteria: \[1\] physician's global assessment of disease activity (PGA), \[2\] subject's assessment of disease activity, \[3\] subject's assessment of pain, \[4\] subject's assessment of physical disability via a health assessment questionnaire disability index(HAQ-DI), and \[5\] C-reactive protein (CRP) at each visit.
Time frame: Every 4 weeks up to Week 24 and every 12 weeks thereafter until study completion or discontinuation (Final value)
Mean Change From Baseline in Tender Joint Count (TJC; Max = 68), a Component of the ACR Criteria, by Visit
Mean change from baseline (for subjects without rescue treatment, baseline is from Study M02-575 \[NCT 00647491\]; for subjects with rescue treatment, baseline is from Study M03-651 \[NCT 00235872\]) in TJC (max = 68), a component of the ACR criteria, by visit
Time frame: Every 4 weeks up to Week 24 and every 12 weeks thereafter until study completion or discontinuation (Final value)
Mean Change From Baseline in Swollen Joint Count (SJC, Max = 66), a Component of the ACR Criteria by Visit
Mean change from baseline (for subjects without rescue treatment, baseline is from Study M02-575 \[NCT 00647491\]; for subjects with rescue treatment, baseline is from Study M03-651 \[NCT 00235872\]) in SJC (max = 66), a component of the ACR criteria, by visit
Time frame: Every 4 weeks up to Week 24 and every 12 weeks thereafter until study completion or discontinuation (final value)
Mean Change From Baseline in Physician's Global Assessment of Disease Activity (PGA) Using a Visual Analog Scale (0 - 100 mm With 100 mm Being the Worst Assessment), a Component of the ACR Criteria, by Visit
Mean change from baseline (for subjects without rescue treatment, baseline is from Study M02-575 \[NCT 00647491\]; for subjects with rescue treatment, baseline is from Study M03-651 \[NCT 00235872\]) in PGA (a visual analog scale from 0 - 100 mm with 100 mm being the worst case), a component of the ACR criteria, by visit
Time frame: Every 4 weeks weeks up to Week 24 and every 12 weeks thereafter until study completion or discontinuation (Final value)
Mean Change From Baseline in Subject's Global Assessment of Disease Activity Using a Visual Analog Scale (0 - 100 mm With 100 mm Being the Worst Assessment), a Component of the ACR Criteria, by Visit
mean change from baseline (for subjects without rescue treatment, baseline is from Study M02-575 \[NCT 00647491\]; for subjects with rescue treatment, baseline is from Study M03-651 \[NCT 00235872\]) in subjects global assessment of disease activity (a visual analog scale from 0 - 100 mm with 100 mm being the worst case), a component of the ACR criteria, by visit
Time frame: Every 4 weeks up to Week 24 and every 12 weeks thereafter until study completion or discontinuation (Final value)
Mean Change From Baseline in Subject's Assessment of Pain Using a Visual Analog Scale (0 - 100 mm With 100 mm Being the Worst Pain), a Component of the ACR Criteria, by Visit
Mean change from baseline (for subjects without rescue treatment, baseline is from Study M02-575 \[NCT 00647491\]; for subjects with rescue treatment, baseline is from Study M03-651 \[NCT 00235872\]) in subject's assessment of pain (on a visual analog scale from 0 - 100 mm with 100 mm being the worst pain), a component of the ACR criteria, by visit
Time frame: Every 4 weeks up to Week 24 and every 12 weeks thereafter until study completion or discontinuation (Final Value)
Mean Change From Baseline in Disability Index of the Health Assessment Questionnaire (HAQ), a Component of the ACR Criteria, by Visit
Mean change from baseline (for subjects without rescue treatment, baseline is from Study M02-575 \[NCT 00647491\]; for subjects with rescue treatment, baseline is from Study M03-651 \[NCT 00235872\]) in disability index of the HAQ (includes 20 questions assessing physical function in 8 domains. The questions are evaluated on a scale from 0 - 3 to measure the ability to perform certain activities \[0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do so\]), a component of the ACR criteria by visit
Time frame: Every 4 weeks up to Week 24 and every 12 weeks thereafter until study completion or discontinuation (final value)
Mean Change From Baseline in C-reactive Protein (CRP), a Component of the ACR Criteria by Visit
Mean change from baseline(for subjects without rescue treatment, baseline is from Study M02-575 \[NCT 00647491\]; for subjects with rescue treatment, baseline is from Study M03-651 \[NCT 00235872\]) in CRP (mg/dL), a component of the ACR criteria, by visit
Time frame: Every 4 weeks up to Week 24 and every 12 weeks thereafter until study completion or discontinuation (Final Value)
Presence of Morning Stiffness by Visit
The number of subjects with morning stiffness at each visit among those who had morning stiffness at baseline (64).
Time frame: Every 4 weeks up to Week 24 and every 12 weeks thereafter until study completion or discontinuation (final value)
Duration (Minutes) of the Presence of Morning Stiffness by Visit
Mean change from baseline (for subjects without rescue treatment, baseline is from Study M02-575 \[NCT 00647491\]; for subjects with rescue treatment, baseline is from Study M03-651 \[NCT 00235872\]) in the duration (minutes) of stiffness in the morning.
Time frame: Every 4 weeks up to Week 24 and every 12 weeks thereafter until study completion or discontinuation (final value)
| Milestone | Adalimumab 40 mg or 80 mg Every Other Week (Eow) |
|---|---|
| Started | 88 |
| Completed | 68 |
| Not completed | 20 |
Number of responders with ACR criteria improvement consisting of 20%, 50%, and 70% (ACR20, ACR50, and ACR70, respectively) reduction in tender or swollen joint counts (TJC or SJC, respectively) and 20%, 50%, and 70% improvement, respectively, in 3 of the following 5 criteria: \[1\] physician's global assessment of disease activity (PGA), \[2\] subject's assessment of disease activity, \[3\] subject's assessment of pain, \[4\] subject's assessment of physical disability via a health assessment questionnaire disability index(HAQ-DI), and \[5\] C-reactive protein (CRP) at each visit.
| participants | Adalimumab 40 mg or 80 mg Every Other Week (Eow) |
|---|---|
| Week 0 ACR20 | 66 |
| Week 0 ACR50 | 48 |
| Week 0 ACR70 | 28 |
| Week 4 ACR20 | 64 |
| Week 4 ACR50 | 44 |
| Week 4 ACR70 | 27 |
| Week 8 ACR20 | 69 |
| Week 8 ACR50 | 45 |
| Week 8 ACR70 | 32 |
| Week 12 ACR20 | 68 |
| Week 12 ACR50 | 50 |
| Week 12 ACR70 | 30 |
| Week 16 ACR20 | 67 |
| Week 16 ACR50 | 49 |
| Week 16 ACR70 | 30 |
| Week 20 ACR20 | 68 |
| Week 20 ACR50 | 49 |
| Week 20 ACR70 | 31 |
| Week 24 ACR20 | 63 |
| Week 24 ACR50 | 48 |
| Week 24 ACR70 | 29 |
| Week 36 ACR20 | 64 |
| Week 36 ACR50 | 45 |
| Week 36 ACR70 | 32 |
| Week 48 ACR20 | 62 |
| Week 48 ACR50 | 46 |
| Week 48 ACR70 | 27 |
| Week 60 ACR20 | 56 |
| Week 60 ACR50 | 44 |
| Week 60 ACR70 | 28 |
| Week 72 ACR20 | 57 |
| Week 72 ACR50 | 47 |
| Week 72 ACR70 | 32 |
| Week 84 ACR20 | 57 |
| Week 84 ACR50 | 42 |
| Week 84 ACR70 | 29 |
| Week 96 ACR20 | 56 |
| Week 96 ACR50 | 43 |
| Week 96 ACR70 | 27 |
| Week 108 ACR20 | 54 |
| Week 108 ACR50 | 45 |
| Week 108 ACR70 | 29 |
| Week 120 ACR20 | 28 |
| Week 120 ACR50 | 24 |
| Week 120 ACR70 | 16 |
| Week 132 ACR20 | 7 |
| Week 132 ACR50 | 3 |
| Week 132 ACR70 | 3 |
| Final Value ACR20 | 62 |
| Final Value ACR50 | 49 |
| Final Value ACR70 | 35 |
Mean change from baseline (for subjects without rescue treatment, baseline is from Study M02-575 \[NCT 00647491\]; for subjects with rescue treatment, baseline is from Study M03-651 \[NCT 00235872\]) in TJC (max = 68), a component of the ACR criteria, by visit
| TJC | Adalimumab 40 mg or 80 mg Every Other Week (Eow) |
|---|---|
| Baseline | 20.5 ± 12.1 |
| Week 0 | -15.3 ± 11.3 |
| Week 4 | -14.9 ± 11.4 |
| Week 8 | -15.3 ± 11.1 |
| Week 12 | -14.8 ± 10.7 |
| Week 16 | -14.7 ± 10.8 |
| Week 20 | -15.2 ± 10.6 |
| Week 24 | -15.5 ± 10.9 |
| Week 36 | -14.9 ± 10.9 |
| Week 48 | -15.0 ± 11.5 |
| Week 60 | -15.4 ± 11.4 |
| Week 72 | -15.7 ± 11.5 |
| Week 84 | -16.1 ± 11.3 |
| Week 96 | -16.8 ± 11.8 |
| Week 108 | -16.5 ± 11.6 |
| Week 120 | -18.1 ± 12.4 |
| Week 132 | -19.4 ± 9.5 |
| Final | -14.9 ± 12.1 |
Mean change from baseline (for subjects without rescue treatment, baseline is from Study M02-575 \[NCT 00647491\]; for subjects with rescue treatment, baseline is from Study M03-651 \[NCT 00235872\]) in SJC (max = 66), a component of the ACR criteria, by visit
| SJC | Adalimumab 40 mg or 80 mg Every Other Week (Eow) |
|---|---|
| Baseline | 15.8 ± 8.6 |
| Week 0 | -11.9 ± 8.3 |
| Week 4 | -11.9 ± 8.3 |
| Week 8 | -12.3 ± 8.0 |
| Week 12 | -11.9 ± 7.7 |
| Week 16 | -12.1 ± 7.8 |
| Week 20 | -11.9 ± 8.3 |
| Week 24 | -11.9 ± 8.3 |
| Week 36 | -11.6 ± 8.3 |
| Week 48 | -11.5 ± 8.8 |
| Week 60 | -11.5 ± 8.4 |
| Week 72 | -12.2 ± 7.8 |
| Week 84 | -12.3 ± 7.8 |
| Week 96 | -12.0 ± 7.8 |
| Week 108 | -12.0 ± 8.2 |
| Week 120 | -12.5 ± 8.7 |
| Week 132 | -12.9 ± 8.0 |
| Final | -11.6 ± 8.0 |
Mean change from baseline (for subjects without rescue treatment, baseline is from Study M02-575 \[NCT 00647491\]; for subjects with rescue treatment, baseline is from Study M03-651 \[NCT 00235872\]) in PGA (a visual analog scale from 0 - 100 mm with 100 mm being the worst case), a component of the ACR criteria, by visit
| mm on a scale | Adalimumab 40 mg or 80 mg Every Other Week (Eow) |
|---|---|
| Baseline | 63.2 ± 21.8 |
| Week 0 | -41.0 ± 26.2 |
| Week 4 | -39.5 ± 27.0 |
| Week 8 | -43.3 ± 23.2 |
| Week 12 | -41.6 ± 24.9 |
| Week 16 | -42.1 ± 25.5 |
| Week 20 | -44.0 ± 24.6 |
| Week 24 | -42.3 ± 26.2 |
| Week 36 | -42.2 ± 25.8 |
| Week 48 | -41.4 ± 27.9 |
| Week 60 | -40.7 ± 28.3 |
| Week 72 | -42.2 ± 26.5 |
| Week 84 | -41.9 ± 26.2 |
| Week 96 | -44.6 ± 24.1 |
| Week 108 | -44.7 ± 25.9 |
| Week 120 | -48.8 ± 27.4 |
| Week 132 | -62.4 ± 10.7 |
| Final | -38.8 ± 31.9 |
mean change from baseline (for subjects without rescue treatment, baseline is from Study M02-575 \[NCT 00647491\]; for subjects with rescue treatment, baseline is from Study M03-651 \[NCT 00235872\]) in subjects global assessment of disease activity (a visual analog scale from 0 - 100 mm with 100 mm being the worst case), a component of the ACR criteria, by visit
| mm on a scale | Adalimumab 40 mg or 80 mg Every Other Week (Eow) |
|---|---|
| Baseline | 58.4 ± 26.8 |
| Week 0 | -34.0 ± 29.8 |
| Week 4 | -32.2 ± 31.1 |
| Week 8 | -33.4 ± 29.2 |
| Week 12 | -33.9 ± 29.3 |
| Week 16 | -33.2 ± 30.9 |
| Week 20 | -34.9 ± 30.4 |
| Week 24 | -33.1 ± 30.9 |
| Week 36 | -31.6 ± 34.6 |
| Week 48 | -33.3 ± 34.0 |
| Week 60 | -30.7 ± 33.6 |
| Week 72 | -33.9 ± 33.1 |
| Week 84 | -31.1 ± 32.2 |
| Week 96 | -31.7 ± 30.4 |
| Week 108 | -33.0 ± 34.0 |
| Week 120 | -37.9 ± 29.4 |
| Week 132 | -37.0 ± 31.7 |
| Final | -29.5 ± 35.7 |
Mean change from baseline (for subjects without rescue treatment, baseline is from Study M02-575 \[NCT 00647491\]; for subjects with rescue treatment, baseline is from Study M03-651 \[NCT 00235872\]) in subject's assessment of pain (on a visual analog scale from 0 - 100 mm with 100 mm being the worst pain), a component of the ACR criteria, by visit
| mm on a scale | Adalimumab 40 mg or 80 mg Every Other Week (Eow) |
|---|---|
| Baseline | 57.8 ± 27.1 |
| Week 0 | -33.6 ± 27.7 |
| Week 4 | -31.8 ± 29.6 |
| Week 8 | -33.7 ± 28.1 |
| Week 12 | -33.3 ± 27.7 |
| Week 16 | -32.5 ± 29.7 |
| Week 20 | -33.0 ± 29.9 |
| Week 24 | -34.0 ± 29.3 |
| Week 36 | -30.6 ± 33.3 |
| Week 48 | -32.1 ± 31.7 |
| Week 60 | -30.4 ± 32.8 |
| Week 72 | -33.4 ± 31.2 |
| Week 84 | -30.8 ± 31.3 |
| Week 96 | -32.0 ± 28.3 |
| Week 108 | -31.9 ± 32.1 |
| Week 120 | -33.5 ± 31.1 |
| Week 132 | -38.9 ± 27.1 |
| Final | -29.1 ± 35.8 |
Mean change from baseline (for subjects without rescue treatment, baseline is from Study M02-575 \[NCT 00647491\]; for subjects with rescue treatment, baseline is from Study M03-651 \[NCT 00235872\]) in disability index of the HAQ (includes 20 questions assessing physical function in 8 domains. The questions are evaluated on a scale from 0 - 3 to measure the ability to perform certain activities \[0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do so\]), a component of the ACR criteria by visit
| units on a scale | Adalimumab 40 mg or 80 mg Every Other Week (Eow) |
|---|---|
| Baseline | 1.4 ± 0.7 |
| Week 0 | -0.5 ± 0.5 |
| Week 4 | -0.5 ± 0.6 |
| Week 8 | -0.6 ± 0.6 |
| Week 12 | -0.6 ± 0.6 |
| Week 16 | -0.6 ± 0.6 |
| Week 20 | -0.6 ± 0.6 |
| Week 24 | -0.6 ± 0.6 |
| Week 36 | -0.5 ± 0.6 |
| Week 48 | -0.6 ± 0.6 |
| Week 60 | -0.5 ± 0.6 |
| Week 72 | -0.6 ± 0.6 |
| Week 84 | -0.5 ± 0.6 |
| Week 96 | -0.5 ± 0.6 |
| Week 108 | -0.6 ± 0.6 |
| Week 120 | -0.6 ± 0.6 |
| Week 132 | -0.7 ± 0.9 |
| Final | -0.5 ± 0.7 |
Mean change from baseline(for subjects without rescue treatment, baseline is from Study M02-575 \[NCT 00647491\]; for subjects with rescue treatment, baseline is from Study M03-651 \[NCT 00235872\]) in CRP (mg/dL), a component of the ACR criteria, by visit
| mg/dL | Adalimumab 40 mg or 80 mg Every Other Week (Eow) |
|---|---|
| Baseline | 4.0 ± 2.7 |
| Week 0 | -2.5 ± 2.9 |
| Week 4 | -2.4 ± 3.0 |
| Week 8 | -2.5 ± 2.9 |
| Week 12 | -2.6 ± 2.9 |
| Week 16 | -2.6 ± 2.8 |
| Week 20 | -2.8 ± 2.7 |
| Week 24 | -2.8 ± 2.8 |
| Week 36 | -2.8 ± 3.0 |
| Week 48 | -2.7 ± 3.0 |
| Week 60 | -2.3 ± 3.6 |
| Week 72 | -2.5 ± 3.1 |
| Week 84 | -2.7 ± 3.0 |
| Week 96 | -2.8 ± 2.3 |
| Week 108 | -2.9 ± 2.4 |
| Week 120 | -2.8 ± 2.3 |
| Week 132 | -2.9 ± 1.9 |
| Final | -2.2 ± 4.1 |
The number of subjects with morning stiffness at each visit among those who had morning stiffness at baseline (64).
| participants | Adalimumab 40 mg or 80 mg Every Other Week (Eow) |
|---|---|
| Week 0 | 24 |
| Week 4 | 29 |
| Week 8 | 26 |
| Week 12 | 25 |
| Week 16 | 24 |
| Week 20 | 23 |
| Week 24 | 23 |
| Week 36 | 22 |
| Week 48 | 19 |
| Week 60 | 23 |
| Week 72 | 20 |
| Week 84 | 21 |
| Week 96 | 15 |
| Week 108 | 15 |
| Week 120 | 7 |
| Week 132 | 1 |
| Final | 22 |
Mean change from baseline (for subjects without rescue treatment, baseline is from Study M02-575 \[NCT 00647491\]; for subjects with rescue treatment, baseline is from Study M03-651 \[NCT 00235872\]) in the duration (minutes) of stiffness in the morning.
| minutes | Adalimumab 40 mg or 80 mg Every Other Week (Eow) |
|---|---|
| Baseline | 164.7 ± 333.9 |
| Week 0 | -119.1 ± 273.0 |
| Week 4 | -98.5 ± 214.8 |
| Week 8 | -122.3 ± 271.8 |
| Week 12 | -100.3 ± 234.9 |
| Week 16 | -120.1 ± 273.3 |
| Week 20 | -123.2 ± 277.2 |
| Week 24 | -120.1 ± 277.8 |
| Week 36 | -104.8 ± 238.0 |
| Week 48 | -104.2 ± 243.7 |
| Week 60 | -95.7 ± 245.8 |
| Week 72 | -102.3 ± 250.4 |
| Week 84 | -103.9 ± 253.4 |
| Week 96 | -115.5 ± 256.2 |
| Week 108 | -120.2 ± 351.8 |
| Week 120 | -115.9 ± 257.3 |
| Week 132 | -75.0 ± 89.8 |
| Final | -97.9 ± 381.3 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adalimumab 40 mg or 80 mg Every Other Week (Eow) | — | 20/88 (22.7%) | 84/88 (95.5%) |
| Event | Adalimumab 40 mg or 80 mg Every Other Week (Eow) |
|---|---|
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 4/88 |
| Joint destructionMusculoskeletal and connective tissue disorders | 3/88 |
| Urinary tract infectionInfections and infestations | 2/88 |
| Clavicle fractureInjury, poisoning and procedural complications | 2/88 |
| Angina pectorisCardiac disorders | 1/88 |
| Atrial thrombosisCardiac disorders | 1/88 |
| Cardiac failureCardiac disorders | 1/88 |
| Vertigo positionalEar and labyrinth disorders | 1/88 |
| CataractEye disorders | 1/88 |
| EnterocolitisGastrointestinal disorders | 1/88 |
| Event | Adalimumab 40 mg or 80 mg Every Other Week (Eow) |
|---|---|
| NasopharyngitisInfections and infestations | 53/88 |
| Adverse drug reactionGeneral disorders | 26/88 |
| Antinuclear antibody positiveInvestigations | 14/88 |
| ConstipationGastrointestinal disorders | 13/88 |
| BronchitisInfections and infestations | 12/88 |
| Dental cariesGastrointestinal disorders | 11/88 |
| ContusionInjury, poisoning and procedural complications | 11/88 |
| Upper respiratory tract infectionInfections and infestations | 9/88 |
| FallInjury, poisoning and procedural complications | 9/88 |
| DNA antibody positiveInvestigations | 9/88 |
| Age Continuous(years) | Adalimumab 40 mg or 80 mg Every Other Week (Eow) |
|---|---|
| Mean | 52.3 ± 11.0 |
| Sex: Female, Male(Participants) | Adalimumab 40 mg or 80 mg Every Other Week (Eow) |
|---|---|
| Female | 67 |
| Male | 21 |
| Region of Enrollment(participants) | Adalimumab 40 mg or 80 mg Every Other Week (Eow) |
|---|---|
| Japan | 88 |
The record gives a start of Mar 2006 and a primary completion of Nov 2006. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2010, 3 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab